Dalpiciclib is a drug for the treatment of various forms of cancer.[1]
In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.[2]
Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.[3]
^Chen X, Shen K (June 2023). "Dalpiciclib in advanced breast cancer". The Lancet. Oncology. 24 (6): 578–579. doi:10.1016/S1470-2045(23)00228-0. PMID 37269836.
^"Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer". hengrui.com.
^Sheikh MS, Satti SA (2021). "The emerging CDK4/6 inhibitor for breast cancer treatment". Molecular and Cellular Pharmacology. 13 (3): 9–12. PMC 8896653. PMID 35251463.
Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment...
The molecular formula C25H30N6O2 may refer to: Dalpiciclib Erdafitinib This set index page lists chemical structure articles associated with the same...
including small cell lung cancer, breast cancer, and colorectal cancer. Dalpiciclib is approved in China for use in combination with fulvestrant for treatment...